Palvella Phase 3 rapamycin trial in microcystic lymphatic malformations positive results, backs 1st-line use
- Palvella plans an H2 2026 NDA filing for QTORIN rapamycin in microcystic lymphatic malformations.
- Positive Phase III CELVA results for QTORIN rapamycin were disclosed during the company's Q4 2025 earnings call.
- Non-GAAP EPS $-1.08 declined 4% YoY in Q4 2025, missing analyst EPS estimates for the quarter.
- Q4 2025 revenue was $0, beating analyst revenue estimates for the quarter.
- Pro forma cash of about $274 million is calculated after a February equity raise.
- Company reported full-year 2025 results alongside its cash update and QTORIN rapamycin regulatory plans.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.